- Home
- WIMI vs ENTA Comparison
WIMI vs ENTA Comparison
Compare WIMI & ENTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WIMI
- ENTA
- Stock Information
- Founded
- WIMI 2015
- ENTA 1995
- Country
- WIMI China
- ENTA United States
- Employees
- WIMI N/A
- ENTA N/A
- Industry
- WIMI Computer Software: Prepackaged Software
- ENTA Biotechnology: Pharmaceutical Preparations
- Sector
- WIMI Technology
- ENTA Health Care
- Exchange
- WIMI Nasdaq
- ENTA Nasdaq
- Market Cap
- WIMI 92.2M
- ENTA 109.0M
- IPO Year
- WIMI 2020
- ENTA 2013
- Fundamental
- Price
- WIMI $0.89
- ENTA $5.09
- Analyst Decision
- WIMI
- ENTA Buy
- Analyst Count
- WIMI 0
- ENTA 4
- Target Price
- WIMI N/A
- ENTA $17.25
- AVG Volume (30 Days)
- WIMI 7.4M
- ENTA 503.4K
- Earning Date
- WIMI 01-01-0001
- ENTA 02-18-2025
- Dividend Yield
- WIMI N/A
- ENTA N/A
- EPS Growth
- WIMI N/A
- ENTA N/A
- EPS
- WIMI N/A
- ENTA N/A
- Revenue
- WIMI $84,137,968.00
- ENTA $67,635,000.00
- Revenue This Year
- WIMI N/A
- ENTA $8.11
- Revenue Next Year
- WIMI N/A
- ENTA N/A
- P/E Ratio
- WIMI N/A
- ENTA N/A
- Revenue Growth
- WIMI 19.25
- ENTA N/A
- 52 Week Low
- WIMI $0.62
- ENTA $4.71
- 52 Week High
- WIMI $2.92
- ENTA $17.80
- Technical
- Relative Strength Index (RSI)
- WIMI 42.64
- ENTA 38.07
- Support Level
- WIMI $0.83
- ENTA $4.94
- Resistance Level
- WIMI $1.06
- ENTA $5.31
- Average True Range (ATR)
- WIMI 0.14
- ENTA 0.32
- MACD
- WIMI -0.04
- ENTA 0.11
- Stochastic Oscillator
- WIMI 13.95
- ENTA 39.05
About WIMI WiMi Hologram Cloud Inc.
WiMi Hologram Cloud Inc and its subsidiaries offer augmented reality (AR) based holographic services and products to cater to its customers. Its AR service and product offerings primarily consist of holographic AR advertising services and holographic AR entertainment products. It is also into the semiconductor business, in which the company provides central processing algorithm services and computer chip products to enterprise customers and the sales of comprehensive solutions for central processing algorithms and related services with software and hardware integration. The company reports in three segments: AR advertising, AR entertainment, and Semiconductor. Its geographical segments are Mainland China, Hong Kong, and International.
About ENTA Enanta Pharmaceuticals Inc.
Enanta Pharmaceuticals Inc is an American biotechnology company which uses robust, chemistry-driven approach and drug discovery capabilities to focus on the research and development of molecule drugs to cure viral infections and liver diseases. Uses virology and immunology method for curing the diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.